GSK PLC (GS71.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:GS71 - GB00BN7SWP63 - Common Stock
GS71.DE Key Statistics, Chart & Performance
The current stock price of GS71.DE is 21.75 EUR. In the past month the price increased by 5.12%. In the past year, price increased by 33.97%.
GS71.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SNW.DE | SANOFI | 11.11 | 205.06B | ||
| SAN.PA | SANOFI | 11.11 | 205.10B | ||
| 1SAN.MI | SANOFI | 10.89 | 201.12B | ||
| MRK.DE | MERCK KGAA | 15.04 | 55.78B | ||
| UCB.BR | UCB SA | 39.69 | 49.56B | ||
| UNC.DE | UCB SA | 39.33 | 49.11B | ||
| BAYN.DE | BAYER AG-REG | 7.28 | 38.20B | ||
| 1BAYN.MI | BAYER AG-REG | 7.28 | 38.20B | ||
| IPN.PA | IPSEN | 12.41 | 10.68B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 25.17 | 10.37B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 108.17 | 10.01B | ||
| 1JAZZ.MI | JAZZ PHARMACEUTICALS PLC | 21.05 | 8.94B |
Related stock screener links
About GS71.DE
Company Profile
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex and currently employs 68,629 full-time employees. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. The company develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
Company Info
GSK PLC
980 Great West Road
Brentford MIDDLESEX GB
Employees: 68629
Phone: 442080475000
GSK PLC / GS71.DE FAQ
Can you describe the business of GSK PLC?
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex and currently employs 68,629 full-time employees. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. The company develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
What is the stock price of GSK PLC today?
The current stock price of GS71.DE is 21.75 EUR. The price decreased by -0.23% in the last trading session.
What is the dividend status of GSK PLC?
GSK PLC (GS71.DE) has a dividend yield of 3.51%. The yearly dividend amount is currently 0.68.
What is the ChartMill rating of GSK PLC stock?
GS71.DE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
On which exchange is GS71.DE stock listed?
GS71.DE stock is listed on the Frankfurt Stock Exchange exchange.
What is the expected growth for GS71 stock?
The Revenue of GSK PLC (GS71.DE) is expected to grow by 4.28% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Who owns GSK PLC?
You can find the ownership structure of GSK PLC (GS71.DE) on the Ownership tab.
GS71.DE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GS71.DE. When comparing the yearly performance of all stocks, GS71.DE is one of the better performing stocks in the market, outperforming 86.71% of all stocks.
GS71.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to GS71.DE. While GS71.DE has a great profitability rating, there are quite some concerns on its financial health.
GS71.DE Financial Highlights
Over the last trailing twelve months GS71.DE reported a non-GAAP Earnings per Share(EPS) of 1.95. The EPS increased by 2.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.08% | ||
| ROA | 8.96% | ||
| ROE | 34.02% | ||
| Debt/Equity | 0.92 |
GS71.DE Forecast & Estimates
31 analysts have analysed GS71.DE and the average price target is 21.19 EUR. This implies a price decrease of -2.56% is expected in the next year compared to the current price of 21.75.
For the next year, analysts expect an EPS growth of 7.61% and a revenue growth 4.28% for GS71.DE